ARMP

Armata Pharmaceuticals Inc

3.87

Nov 13 • 3:59 PM ET +0.15 (4.03%)

3.87

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro AMEX

Nov 12, 6:45 PMArmata Pharmaceuticals Inc reports fiscal Q3 2026 results with non-GAAP EPS $-0.24 (+68% YoY) and revenue $3.2M (+174% YoY), beats EPS and revenue estimates

Peers: SPRO ANTX NIKI IVVD ACXP CPIX MCRB VIR TOVX SCYX

| Held by: VTI IWM VXF IWO VTWO BUSM IWC VTWG RSSL ITWO

Scroll to Statements

Index	RUT
Market Cap	143.94M
Enterprise Value	377.20M
Income	-122.86M
Sales	7.55M
Book/sh	-4.68
Cash/sh	0.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	61
IPO	May 20, 1994

P/E	-
Forward P/E	-
PEG	-
P/S	19.06
P/B	-
P/C	7.86
P/FCF	-
EV/EBITDA	-
EV/Sales	49.96
Quick Ratio	0.12
Current Ratio	0.12
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-7.08
EPS next Y	-1.39
EPS next Q	-0.37
EPS this Y	83.33%
EPS next Y	-73.12%
EPS next 5Y	38.99%
EPS past 3/5Y	-64.55% -28.83%
Sales past 3/5Y	-3.80% 42.90%
EPS Y/Y TTM	-163.53%
Sales Y/Y TTM	49.49%
EPS Q/Q	68.07%
Sales Q/Q	173.60%
Earnings	Nov 12 AMC
EPS/Sales Surpr.	56.76% 604.67%

Insider Own	67.99%
Insider Trans	0.00%
Inst Own	13.92%
Inst Trans	2.57%
ROA	-141.23%
ROE	-
ROIC	-
Gross Margin	73.02%
Oper. Margin	-461.83%
Profit Margin	-1626.27%
SMA20	14.16%
SMA50	1.90%
SMA200	-43.70%
Trades

Shs Outstand	37.19M
Shs Float	11.91M
Short Float	7.66%
Short Ratio	5.02
Short Interest	0.91M
52W High	14.98 -74.17%
52W Low	2.74 40.98%
Volatility	11.20% 11.43%
ATR (14)	0.38
RSI (14)	56.23
Beta	1.63
Rel Volume	0.16
Avg Volume	181.73K
Volume	28,612

Perf Week	10.26%
Perf Month	25.24%
Perf Quarter	-13.62%
Perf Half Y	-51.93%
Perf YTD	-38.38%
Perf Year	-39.34%
Perf 3Y	57.32%
Perf 5Y	14.84%
Perf 10Y	-97.18%
Recom	1.00
Target Price	17.50
Prev Close	3.72
Price	3.87
Change %	4.03%

Consensus

Strong Buy

Avg. Price Target

$17.50

Implied Upside

+352.2%

Analysts1incl. previous ratings

Rating Distribution1 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 19, 2019	Initiated	LLadenburg Thalmann	Buy	$9	+132.6%

Nov-12-26 04:05PM	Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update (PR Newswire)
Oct-07-26 07:00AM	Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States (PR Newswire)
Sep-23-26 07:00AM	Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development (PR Newswire) -13.33%
Sep-21-26 07:00AM	Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates (PR Newswire)
Sep-14-26 09:34AM	Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation (InvestorsHub)
07:00AM	Loading…
07:00AM	Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 (PR Newswire)
Sep-10-26 07:00AM	Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
Sep-03-26 07:00AM	Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials (PR Newswire)
Aug-12-26 04:05PM	Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update (PR Newswire) +11.83%
Jul-20-26 07:00AM	Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 (PR Newswire) +12.20%
Jul-13-26 07:00AM	Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia (PR Newswire) -6.81%
Jun-23-26 07:00AM	Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 (PR Newswire)
May-13-26 04:30PM	Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update (PR Newswire) -7.03%
May-07-26 07:00AM	Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 (PR Newswire)
May-04-26 07:00AM	Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" (PR Newswire) +10.80%
07:00AM	Loading…
Apr-27-26 07:00AM	Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors (PR Newswire) -14.86%
Mar-25-26 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results (PR Newswire) +8.59%
Mar-19-26 07:00AM	Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update (PR Newswire)
Mar-02-26 10:23AM	H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod (Insider Monkey) +6.13%
Feb-23-26 07:00AM	Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 (PR Newswire) +9.28%
Jan-13-26 07:00AM	Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus (PR Newswire)
Nov-18-25 07:00AM	Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST (PR Newswire)
Nov-12-25 05:25PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update (PR Newswire)
Nov-10-25 08:40AM	Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates (Zacks) +7.44%
07:00AM	Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California (PR Newswire)
Nov-06-25 08:15PM	Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 06:05PM	Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates (Zacks)
Oct-23-25 07:10AM	Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? (Zacks)
Oct-22-25 11:10AM	Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025 (PR Newswire) +103.17%
07:00AM	Loading…
Oct-14-25 07:00AM	Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025 (PR Newswire)
Oct-06-25 09:40AM	Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? (Zacks)
Sep-18-25 09:40AM	Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-08-25 07:00AM	Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology (PR Newswire)
Sep-04-25 07:00AM	Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Sep-01-25 09:40AM	Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-15-25 12:00PM	All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy (Zacks)
09:40AM	Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-12-25 05:40PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update (PR Newswire)
May-21-25 09:50AM	ARMP Soars 72% in a Month Following Infectious Disease Study Success (Zacks) -6.67%
May-19-25 07:00AM	Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia (PR Newswire) +75.56%
May-14-25 05:45PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update (PR Newswire)
09:10AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-12-25 05:55PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +9.23%
May-08-25 07:10AM	New Strong Sell Stocks for May 8th (Zacks)
May-01-25 07:00AM	Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 (PR Newswire) -15.41%
Apr-28-25 04:53AM	New Strong Sell Stocks for April 28th (Zacks)
Apr-24-25 06:25AM	New Strong Sell Stocks for April 24th (Zacks)
Apr-09-25 05:24AM	New Strong Sell Stocks for April 9th (Zacks) -14.80%
Mar-20-25 05:56PM	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update (PR Newswire) -10.95%
Mar-12-25 05:08PM	Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva (PR Newswire)
Mar-11-25 07:00AM	Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit (PR Newswire) -6.50%
Dec-20-24 07:15AM	Armata Pharmas inhaled AP-PA02 shows positive results in Phase 2 study (TipRanks)
Dec-19-24 07:00AM	Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection (PR Newswire)
Nov-19-24 07:00AM	Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting (PR Newswire) -11.61%
Nov-13-24 04:05PM	Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update (PR Newswire)
Nov-12-24 07:00AM	Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia (PR Newswire) +22.22%
Oct-30-24 07:00AM	Armata Pharmaceuticals Announces Structural Biology Publication (PR Newswire)
Sep-12-24 12:00PM	Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Sep-05-24 07:30AM	Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-26-24 07:30AM	Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium (PR Newswire)
Aug-15-24 04:45PM	Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer (PR Newswire) -6.97%
Aug-13-24 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update (PR Newswire) +6.27% -10.70%
Jul-30-24 07:00AM	Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 (PR Newswire)
Jul-11-24 07:00AM	Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection (PR Newswire) +11.94%
Jul-10-24 04:05PM	Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 (PR Newswire) +5.10%
May-07-24 04:01PM	Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update (PR Newswire) +13.94%
Mar-21-24 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update (PR Newswire)
Mar-04-24 04:01PM	Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva (PR Newswire) -8.50%
Feb-21-24 07:00AM	Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit (PR Newswire)
Nov-14-23 04:00PM	Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update (PR Newswire) +8.94% -19.78%
Oct-30-23 08:00AM	Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference (PR Newswire) +10.19%
Oct-19-23 08:00AM	Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 (PR Newswire)
Sep-26-23 08:00AM	Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus (PR Newswire)
Sep-21-23 07:00AM	Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference (PR Newswire)
Aug-17-23 09:55AM	Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Aug-14-23 07:00AM	Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update (PR Newswire)
Jul-11-23 08:00AM	Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics (PR Newswire)
May-31-23 08:00AM	Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy (PR Newswire)
May-11-23 04:05PM	Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update (PR Newswire)
Mar-16-23 04:10PM	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update (PR Newswire) +5.42% +8.57%
Mar-06-23 06:00AM	Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis (PR Newswire) +10.87%
Jan-10-23 04:05PM	Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC (PR Newswire) +25.38%
Dec-22-22 08:00AM	Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection (PR Newswire) -6.99%
Dec-08-22 09:55AM	Armata Pharmaceuticals, Inc. (ARMP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-28-22 09:35AM	After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP) (Zacks)
08:00AM	Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage (PR Newswire)
Nov-15-22 09:55AM	Here's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom Fishing (Zacks) -9.66%
Nov-09-22 04:15PM	Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update (PR Newswire) -8.23%
Aug-11-22 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update (PR Newswire)
Aug-01-22 08:00AM	Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections (PR Newswire)
May-23-22 08:00AM	Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus (PR Newswire)
May-12-22 04:17PM	Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update (PR Newswire) -5.00%
Mar-31-22 04:05PM	Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva (PR Newswire) -8.60%
Mar-22-22 10:00AM	Wall Street Analysts See a 52% Upside in Armata Pharmaceuticals, Inc. (ARMP): Can the Stock Really Move This High? (Zacks) +5.17%
Mar-17-22 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update (PR Newswire) +5.37% +17.74%
Mar-09-22 05:28PM	Armata Pharmaceuticals to move headquarters to Playa Vista (American City Business Journals)
Feb-22-22 08:00AM	Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis (PR Newswire)

Show Previous News

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

CEO & DirectorDr. Deborah L. Birx M.D.

Chief Financial OfficerMr. David D. House

Chief Business OfficerDr. Pierre Kyme Ph.D.

Vice President of OperationsMr. Peter Hubbard

Head of Regulatory Strategy & OperationsMs. Bani Tchekanova Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

ARMP

Armata Pharmaceuticals Inc

Upgrade your Finviz experience

All the Features.
Half the Price.